Abstract 526P
Background
Tracheal, Bronchus, and Lung (TBL) cancer is the 1st leading cause of deaths across Southeast Asia (SEA), East Asia (EA), and Oceania (OC). However, there has been a lack of estimates regarding the burden of TBL cancer across these regions in previous studies.
Methods
Utilizing the Global Burden of Disease Methodology, TBL cancer prevalence, incidence, mortality, and disabiity adjusted life years (DALYs) were analyzed by age, sex, year, across SEA, EA, and OC spanning from 1990-2019. We employed a regression framework to forecast TBL cancer deaths through 2040.
Results
The total prevalence of TBL cancer cases surged by 3.5 times, escalating from 344,251 (95% uncertainty interval: 301,687-388,590) in 1990 to 1,306,745 (1,116,313-1,513,254) in 2019. While deaths rose from 319,128 (282,904-359,206) to 914,442 (791,095-1,049,894) from 1990-2019. In terms of the age-standardized incidence rate (ASIR), there was an increase from 27.81 (24.65-31.15) to 37.13 (32.08-42.53) per 100,000 person years from 1990-2019. The highest annual percentage of change (APC) was witnessed in deaths, rising by 187%, and in DALYs, increasing by 143% from 1990-2019. Notably, China experienced the highest APC in ASIR (38%), followed by Indonesia (35%), and Taiwan (28%) from 1990-2019. Meanwhile, Indonesia exhibited the highest increase in age-standardized mortality rate (ASMR) at 36%, while the Maldives demonstrated the most notable decrease of 33% from 1990-2019. In 2019, individuals aged 65-69 accounted for the highest incidence (172,031), while those aged 70-74 saw the highest mortality (155,538). Moreover, male individuals consistently bore a greater burden than females over the past three decades. Projection indicates that the total number of deaths may reach 1,080,050 (705,751-1,800,670) by 2040.
Conclusions
TBL cancer constituted 26.21% of all deaths within the realm of cancer-related fatalities in SEA, EA, and OC in 2019. This study uncovers a consistent pattern of escalating burden, emphasizing a notable rise in fatalities and its implications for public health, necessitates comprehensive strategies that encompass both individual risk factors and systemic challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract